<p>药明康德公司（NYSE:PRGO - 获取免费报告）目前被五家评级机构给予了 “持有” 的平均推荐，Marketbeat 报道称。三位研究分析师对该股票给予了持有推荐，另外两位则给予了买入推荐。在过去一年中，发布报告的经纪人对该股票的平均一年目标价格为 35.00 美元。</p>
<p>几位股票分析师对该公司进行了评论。杰富瑞金融集团在 9 月 23 日的报告中重申了 “持有” 评级，并将药明康德的目标价格下调至 30.00 美元（之前为 50.00 美元）。派珀·桑德勒在 1 月 6 日的研究报告中将药明康德的股票评级从 “增持” 下调至 “中性”，并将其目标价格从 34.00 美元下调至 27.00 美元。Canaccord Genuity Group 在 9 月 30 日的研究报告中重申了 “买入” 评级，并将药明康德的目标价格设定为 42.00 美元。StockNews.com 在周六的研究报告中将药明康德的股票评级从 “买入” 下调至 “持有”。最后，Argus 在周二的研究报告中将药明康德的股票评级从 “买入” 下调至 “持有”。</p>
<p><strong>获取我们关于 PRGO 的最新研究报告</strong></p>
<h2>药明康德股票表现</h2>
<p>周二中午交易时，PRGO 的股票下跌了 0.58 美元，报 23.76 美元。该公司的股票交易量为 98,548 股，而其平均交易量为 1,370,925 股。药明康德的股价一年低点为 23.73 美元，一年高点为 33.96 美元。该股票的 50 日移动平均线为 26.71 美元，200 日移动平均线为 26.80 美元。该公司的市值为 32.4 亿美元，市盈率为-20.31，贝塔系数为 0.53。该公司的债务与股本比率为 0.94，速动比率为 1.77，流动比率为 2.56。</p>
<p>药明康德（NYSE:PRGO - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为 0.81 美元，符合市场共识预期的 0.81 美元。该公司的季度收入为 10.9 亿美元，而分析师预期为 11.2 亿美元。药明康德的净利润率为-3.64%，股本回报率为 7.38%。该公司的季度收入同比下降了 3.2%。去年同期，该公司每股收益为 0.64 美元。整体来看，卖方分析师预计药明康德在当前年度将发布 2.56 美元的每股收益。</p>
<h2>药明康德宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，该分红于 12 月 17 日支付。11 月 29 日的股东记录显示，股东获得了 0.276 美元的分红。这代表着每年 1.10 美元的分红和 4.65% 的分红收益率。除息日期为 11 月 29 日。药明康德的派息比率为-94.02%。</p>
<h2>药明康德的内部活动</h2>
<p>在其他消息中，董事杰弗里·B·金德勒于 12 月 9 日以 28.27 美元的平均价格出售了 17,598 股股票，总交易额为 497,495.46 美元。出售后，该董事现在持有 5,409 股公司股票，价值约 152,912.43 美元。这代表着其持股比例下降了 76.49%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。当前，0.70% 的股票由内部人士持有。</p>
<h2>机构投资者对药明康德的看法</h2>
<p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。德克萨斯州永久学校基金公司在第二季度增持了药明康德的股份，增幅为 1.2%。德克萨斯州永久学校基金公司现在持有 119,298 股公司股票，价值 3,064,000 美元，此前在该期间内增持了 1,357 股。美国世纪公司在第二季度增持了药明康德的股份，增幅为 13.7%。美国世纪公司现在持有 24,334 股公司股票，价值 625,000 美元，此前在上个季度增持了 2,929 股。Dimensional Fund Advisors LP 在第二季度增持了药明康德的股份，增幅为 3.6%。Dimensional Fund Advisors LP 现在持有 7,162,656 股公司股票，价值 183,935,000 美元，此前在该期间内增持了 249,640 股。明治安田资产管理有限公司在第二季度增持了药明康德的股份，增幅为 4.2%。明治安田资产管理有限公司现在持有 301,570 股公司股票，价值 7,744,000 美元，此前在上个季度增持了 12,254 股。最后，合并银行在第二季度增持了药明康德的股份，增幅为 3.3%。合并银行现在持有 85,350 股公司股票，价值 2,192,000 美元，此前在上个季度增持了 2,752 股。95.91% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于药明康德</h2>
<p>（获取免费报告）</p>
<p>药明康德公司在美国、欧洲及国际市场提供非处方健康和保健解决方案，以提升个人健康。它通过消费者自我护理美洲和消费者自我护理国际两个部门运营。该公司开发、制造、营销和分销自我护理消费品，包括上呼吸道产品（如止咳药、祛痰药和鼻窦及过敏缓解药）；营养产品，包括婴儿配方奶粉和营养饮料；消化健康产品，包括抗酸药、止泻药和抗胃灼热药；止痛和助眠产品，包括止痛药和退烧药；以及口腔护理产品，包括牙刷、牙刷替换头、牙线、牙线棒、美白产品和牙刷保护套。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票超过培瑞克</li>
<li>制造业股票投资</li>
<li>美联储在 2025 年加息的可能性大于降息</li>
<li>即将到来的 IPO 股票锁定期解析</li>
<li>投资者通过寻求黄金和石油避险来应对不确定性</li>
<li>3 只可以提升您投资组合的家居改善股票</li>
<li>Archer Aviation 股价下滑，现在 2025 年价格便宜</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSR08?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSR08"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>您现在应该投资 1,000 美元在培瑞克吗？</h2>
<p>在您考虑培瑞克之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而培瑞克并不在名单上。</p>
<p>虽然培瑞克目前在分析师中被评为 “持有”，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

培瑞克

<p>Perrigo Company plc（纽约证券交易所代码：PRGO）获得了五位分析师的平均评级为 “持有”，其中三位推荐持有，二位推荐买入。平均目标价为 35.00 美元。最近的评级包括 Jefferies Financial Group 的持有评级，目标价为 30.00 美元，Piper Sandler 的下调至中性，目标价为 27.00 美元，以及 Canaccord Genuity 的买入评级，目标价为 42.00 美元。该股票目前交易价格为 23.76 美元，市值为 32.4 亿美元。Perrigo 还宣布了每季度 0.276 美元的股息，收益率为 4.65%</p>

<p>Perrigo Company plc (NYSE:PRGO - Get Free Report) has been given an average recommendation of &#34;Hold&#34; by the five ratings firms that are currently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $35.00.</p>
<div class="lb-trans"><p>药明康德公司（NYSE:PRGO - 获取免费报告）目前被五家评级机构给予了 “持有” 的平均推荐，Marketbeat 报道称。三位研究分析师对该股票给予了持有推荐，另外两位则给予了买入推荐。在过去一年中，发布报告的经纪人对该股票的平均一年目标价格为 35.00 美元。</p>
</div><p>Several equities analysts have commented on the company. Jefferies Financial Group reaffirmed a &#34;hold&#34; rating and issued a $30.00 price target (down previously from $50.00) on shares of Perrigo in a report on Monday, September 23rd. Piper Sandler downgraded shares of Perrigo from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and decreased their price target for the stock from $34.00 to $27.00 in a research note on Monday, January 6th. Canaccord Genuity Group restated a &#34;buy&#34; rating and issued a $42.00 price objective on shares of Perrigo in a research note on Monday, September 30th. StockNews.com lowered shares of Perrigo from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday. Finally, Argus lowered shares of Perrigo from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday.</p>
<div class="lb-trans"><p>几位股票分析师对该公司进行了评论。杰富瑞金融集团在 9 月 23 日的报告中重申了 “持有” 评级，并将药明康德的目标价格下调至 30.00 美元（之前为 50.00 美元）。派珀·桑德勒在 1 月 6 日的研究报告中将药明康德的股票评级从 “增持” 下调至 “中性”，并将其目标价格从 34.00 美元下调至 27.00 美元。Canaccord Genuity Group 在 9 月 30 日的研究报告中重申了 “买入” 评级，并将药明康德的目标价格设定为 42.00 美元。StockNews.com 在周六的研究报告中将药明康德的股票评级从 “买入” 下调至 “持有”。最后，Argus 在周二的研究报告中将药明康德的股票评级从 “买入” 下调至 “持有”。</p>
</div><p><strong>Get Our Latest Research Report on PRGO</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 PRGO 的最新研究报告</strong></p>
</div><h2>Perrigo Stock Performance</h2>
<div class="lb-trans"><h2>药明康德股票表现</h2>
</div><p>Shares of PRGO traded down $0.58 during mid-day trading on Tuesday, hitting $23.76. The company's stock had a trading volume of 98,548 shares, compared to its average volume of 1,370,925. Perrigo has a one year low of $23.73 and a one year high of $33.96. The stock's 50-day moving average is $26.71 and its two-hundred day moving average is $26.80. The firm has a market capitalization of $3.24 billion, a PE ratio of -20.31 and a beta of 0.53. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56.</p>
<div class="lb-trans"><p>周二中午交易时，PRGO 的股票下跌了 0.58 美元，报 23.76 美元。该公司的股票交易量为 98,548 股，而其平均交易量为 1,370,925 股。药明康德的股价一年低点为 23.73 美元，一年高点为 33.96 美元。该股票的 50 日移动平均线为 26.71 美元，200 日移动平均线为 26.80 美元。该公司的市值为 32.4 亿美元，市盈率为-20.31，贝塔系数为 0.53。该公司的债务与股本比率为 0.94，速动比率为 1.77，流动比率为 2.56。</p>
</div><p>Perrigo (NYSE:PRGO - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.81 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.81. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.12 billion. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The business's quarterly revenue was down 3.2% on a year-over-year basis. During the same period last year, the business posted $0.64 EPS. As a group, sell-side analysts anticipate that Perrigo will post 2.56 EPS for the current year.</p>
<div class="lb-trans"><p>药明康德（NYSE:PRGO - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为 0.81 美元，符合市场共识预期的 0.81 美元。该公司的季度收入为 10.9 亿美元，而分析师预期为 11.2 亿美元。药明康德的净利润率为-3.64%，股本回报率为 7.38%。该公司的季度收入同比下降了 3.2%。去年同期，该公司每股收益为 0.64 美元。整体来看，卖方分析师预计药明康德在当前年度将发布 2.56 美元的每股收益。</p>
</div><h2>Perrigo Announces Dividend</h2>
<div class="lb-trans"><h2>药明康德宣布分红</h2>
</div><p>The company also recently announced a quarterly dividend, which was paid on Tuesday, December 17th. Stockholders of record on Friday, November 29th were issued a $0.276 dividend. This represents a $1.10 annualized dividend and a dividend yield of 4.65%. The ex-dividend date was Friday, November 29th. Perrigo's payout ratio is -94.02%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，该分红于 12 月 17 日支付。11 月 29 日的股东记录显示，股东获得了 0.276 美元的分红。这代表着每年 1.10 美元的分红和 4.65% 的分红收益率。除息日期为 11 月 29 日。药明康德的派息比率为-94.02%。</p>
</div><h2>Insider Activity at Perrigo</h2>
<div class="lb-trans"><h2>药明康德的内部活动</h2>
</div><p>In other news, Director Jeffrey B. Kindler sold 17,598 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $28.27, for a total transaction of $497,495.46. Following the sale, the director now owns 5,409 shares in the company, valued at approximately $152,912.43. This represents a 76.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. 0.70% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事杰弗里·B·金德勒于 12 月 9 日以 28.27 美元的平均价格出售了 17,598 股股票，总交易额为 497,495.46 美元。出售后，该董事现在持有 5,409 股公司股票，价值约 152,912.43 美元。这代表着其持股比例下降了 76.49%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。当前，0.70% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Perrigo</h2>
<div class="lb-trans"><h2>机构投资者对药明康德的看法</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the company. Texas Permanent School Fund Corp grew its position in shares of Perrigo by 1.2% during the 2nd quarter. Texas Permanent School Fund Corp now owns 119,298 shares of the company's stock worth $3,064,000 after buying an additional 1,357 shares during the period. American Century Companies Inc. raised its position in shares of Perrigo by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 24,334 shares of the company's stock valued at $625,000 after acquiring an additional 2,929 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Perrigo by 3.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 7,162,656 shares of the company's stock valued at $183,935,000 after purchasing an additional 249,640 shares during the period. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Perrigo by 4.2% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 301,570 shares of the company's stock worth $7,744,000 after purchasing an additional 12,254 shares during the last quarter. Finally, Amalgamated Bank boosted its position in shares of Perrigo by 3.3% in the 2nd quarter. Amalgamated Bank now owns 85,350 shares of the company's stock worth $2,192,000 after purchasing an additional 2,752 shares during the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。德克萨斯州永久学校基金公司在第二季度增持了药明康德的股份，增幅为 1.2%。德克萨斯州永久学校基金公司现在持有 119,298 股公司股票，价值 3,064,000 美元，此前在该期间内增持了 1,357 股。美国世纪公司在第二季度增持了药明康德的股份，增幅为 13.7%。美国世纪公司现在持有 24,334 股公司股票，价值 625,000 美元，此前在上个季度增持了 2,929 股。Dimensional Fund Advisors LP 在第二季度增持了药明康德的股份，增幅为 3.6%。Dimensional Fund Advisors LP 现在持有 7,162,656 股公司股票，价值 183,935,000 美元，此前在该期间内增持了 249,640 股。明治安田资产管理有限公司在第二季度增持了药明康德的股份，增幅为 4.2%。明治安田资产管理有限公司现在持有 301,570 股公司股票，价值 7,744,000 美元，此前在上个季度增持了 12,254 股。最后，合并银行在第二季度增持了药明康德的股份，增幅为 3.3%。合并银行现在持有 85,350 股公司股票，价值 2,192,000 美元，此前在上个季度增持了 2,752 股。95.91% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Perrigo</h2>
<div class="lb-trans"><h2>关于药明康德</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.</p>
<div class="lb-trans"><p>药明康德公司在美国、欧洲及国际市场提供非处方健康和保健解决方案，以提升个人健康。它通过消费者自我护理美洲和消费者自我护理国际两个部门运营。该公司开发、制造、营销和分销自我护理消费品，包括上呼吸道产品（如止咳药、祛痰药和鼻窦及过敏缓解药）；营养产品，包括婴儿配方奶粉和营养饮料；消化健康产品，包括抗酸药、止泻药和抗胃灼热药；止痛和助眠产品，包括止痛药和退烧药；以及口腔护理产品，包括牙刷、牙刷替换头、牙线、牙线棒、美白产品和牙刷保护套。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Perrigo</li>
<li>Manufacturing Stocks Investing</li>
<li>The Fed Is More Likely to Hike Than Cut Rates in 2025</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Archer Aviation Shares Slide, Now Bargain Priced for 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过培瑞克</li>
<li>制造业股票投资</li>
<li>美联储在 2025 年加息的可能性大于降息</li>
<li>即将到来的 IPO 股票锁定期解析</li>
<li>投资者通过寻求黄金和石油避险来应对不确定性</li>
<li>3 只可以提升您投资组合的家居改善股票</li>
<li>Archer Aviation 股价下滑，现在 2025 年价格便宜</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSR08" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=PRGO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Perrigo Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在培瑞克吗？</h2>
</div><p>Before you consider Perrigo, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑培瑞克之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perrigo wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而培瑞克并不在名单上。</p>
</div><p>While Perrigo currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然培瑞克目前在分析师中被评为 “持有”，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

培瑞克公司（纽约证券交易所代码：PRGO）获得分析师的平均评级为 “持有”